Daklinza

Pharma

AbbVie inks deal to boost Mavyret access in nearly 100 countries

AbbVie inked a deal with the Medicines Patent Pool to boost access to hep C drug Mavyret in nearly 100 low- and middle-income countries and territories.

Eric Sagonowsky Nov 13, 2018 11:40am

AbbVie's pan-genotypic hep C drug Mavyret undercuts competition

Aug 3, 2017 5:21pm

Gilead's Sovaldi patent under fire, this time in Europe

Mar 27, 2017 10:07am

Pharma consultants extol hep C drugs despite high costs

Feb 24, 2017 10:22am

FDA slaps hep B comeback warning on hep C wonder drugs

Oct 5, 2016 10:31am

Pharma-backed initiative delivers low-cost hep C drugs

Apr 18, 2016 3:22am